Clinical Safety and Effectiveness of Tolvaptan for patients with heart falure

Clinical Safety and Effectiveness of Tolvaptan for patients with heart falure - Clinical Safety and Effectiveness of Tolvaptan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031667

Enrollment

700

Registered

2018-03-11

Start date

2017-11-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: acute heart failure cases who admitted at Teikyo University hospital and had oral tolvaptan

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Clinical adverse events in-hospital, at 6 month follow-up, at 12 month follow-up, and at 24 month follow-up (all-cause death, cardiovascular death, worsened heart failure, cerebral infarction, intubation, fetal arrhythmia, discharge postponement, rehospitalization)	—

Countries

Japan

Contacts

Public ContactKataoka Akihisa

Teikyo University Hospital Department of Medicine

kataoaki@sd5.so-net.ne.jp+81-3-3964-1211

Outcome results